Genmab and Synaffix Enter into License Agreement for ADC Technology
- Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
- Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
- Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales of successfully commercialized therapies
COPENHAGEN, Denmark and AMSTERDAM, Netherlands; 4 January, 2022 — Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies. Genmab is granted exclusive research rights to utilize Synaffix ADC technologies for one drug target with the option for the worldwide development and commercialization of the resulting ADCs. Genmab has the option to exercise exclusive research and commercial licenses for additional targets.
